AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure

The unraveling of Exicure continues apace. Weeks after the biotech raised the specter of bankruptcy, AbbVie and Ipsen have terminated their hair loss disorder and rare neurodegenerative disease collaborations with the company.